UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab

AIDS (London), 2017-04, Vol.31 (7), p.1048-1051

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

Cancers, 2020-12, Vol.12 (12), p.3608

2020

Link zum Volltext

Verfügbarkeit prüfen

Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study

Journal of thoracic disease, 2019-04, Vol.11 (4), p.1370-1378

2019

Link zum Volltext

Verfügbarkeit prüfen

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Cancer medicine (Malden, MA), 2020-01, Vol.9 (2), p.432-439

2020

Link zum Volltext

Verfügbarkeit prüfen

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Cancer management and research, 2019-01, Vol.11, p.10821-10826

2019

Link zum Volltext

Verfügbarkeit prüfen

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

The Lancet regional health. Europe, 2022-11, Vol.22, p.100492-100492, Article 100492

2022

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Arthritis & rheumatology (Hoboken, N.J.), 2019-12, Vol.71 (12), p.2100-2111

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.191-197

2023

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study)

Lung cancer (Amsterdam, Netherlands), 2021-11, Vol.161, p.122-127

2021

Link zum Volltext

Verfügbarkeit prüfen

Unusual cause of recurrent pneumothorax: excavated metastasis of osteosarcoma

The Annals of thoracic surgery, 2001-12, Vol.72 (6), p.2111-2113

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 13 von 13

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(13)

Sprache

Englisch
(13)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Oncology
(9)
Humans
(8)
Male
(8)
Middle Aged
(7)
Lung Cancer
(6)
Adult
(5)
Chemotherapy
(5)
Life Sciences
(5)
Metastasis
(5)
Aged
(4)
Female
(4)
Immunotherapy
(4)
Lung Neoplasms - Drug Therapy
(4)
Tumors
(4)
Aged, 80 And Over
(3)
Cancer
(3)
Cancer Therapies
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study)

Unusual cause of recurrent pneumothorax: excavated metastasis of osteosarcoma

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

Suchergebnisse filtern